Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

NCT04895722 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

302

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Pembrolizumab/Quavonlimab
BIOLOGICAL: Pembrolizumab/Favezelimab
BIOLOGICAL: Pembrolizumab/Vibostolimab
BIOLOGICAL: MK-4830

Sponsor

Merck Sharp & Dohme LLC